Florian Selt
163 works · 5,053 citations · h-index 22
Top works
- DNA methylation-based classification of central nervous system tumours
- Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets
- Sarcoma classification by DNA methylation profiling
- Response to trametinib treatment in progressive pediatric low-grade glioma patients
- PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum
- Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification
- Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas
- Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
- Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib
- The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma
- Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions
- Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing
- Advancing CNS tumor diagnostics with expanded DNA methylation-based classification
- Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients
- Decoding pediatric spinal tumors: a single-center retrospective case series on etiology, presentation, therapeutic strategies, and outcomes
- Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells
- Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors
- BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma
- GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types
- The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models